{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:02:28Z","timestamp":1772560948644,"version":"3.50.1"},"reference-count":142,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.hfc.2021.07.006","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T14:13:27Z","timestamp":1635171207000},"page":"73-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis"],"prefix":"10.1016","volume":"18","author":[{"given":"Michele","family":"Lioncino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Monda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Palmiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Caiazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Vetrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Dongiglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Verrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cerciello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiore","family":"Manganelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pacileo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Bossone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Golino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hfc.2021.07.006_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hfc.2021.07.006_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0022-2836(78)90368-6","article-title":"Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 \u00c5","volume":"121","author":"Blake","year":"1978","journal-title":"J\u00a0Mol Biol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1006\/jmbi.1994.1708","article-title":"Crystallization of the macromolecular complex transthyretin-retinol-binding protein","volume":"244","author":"Monaco","year":"1994","journal-title":"J\u00a0Mol Biol"},{"issue":"12","key":"10.1016\/j.hfc.2021.07.006_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1515\/CCLM.2002.213","article-title":"Three-dimensional structure of the transthyretin-binding protein complex","volume":"40","author":"Monaco","year":"2002","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"issue":"24","key":"10.1016\/j.hfc.2021.07.006_bib8","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2021.07.006_bib9","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"38","key":"10.1016\/j.hfc.2021.07.006_bib10","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.hfc.2021.07.006_bib11","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2021.07.006_bib12","article-title":"Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis","author":"Rosenblum","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"10.1016\/j.hfc.2021.07.006_bib13","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.006_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","article-title":"Identification of TTR-related subclinical amyloidosis with 99mtc-dpd scintigraphy","volume":"7","author":"Longhi","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hfc.2021.07.006_bib15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","article-title":"Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population","volume":"270","author":"Mohamed-Salem","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2021.07.006_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1146\/annurev.med.51.1.543","article-title":"The genetics of the amyloidoses","volume":"51","author":"Buxbaum","year":"2000","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A\u00a0peculiar form of peripheral neuropathy: Familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.006_bib18","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.hfc.2021.07.006_bib19","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/13506129.2010.483114","article-title":"Heart complications in familial transthyretin amyloidosis: impact of age and gender","volume":"17","author":"H\u00f6rnsten","year":"2010","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joim.12585","article-title":"One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition","volume":"281","author":"Suhr","year":"2017","journal-title":"J\u00a0Intern Med"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.006_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.006_bib24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (Isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1468-1331.2004.00941.x","article-title":"Phenotypic expression of familial amyloid polyneuropathy in Brazil","volume":"12","author":"Bittencourt","year":"2005","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mus.20644","article-title":"Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal","volume":"35","author":"Concei\u00e7\u00e3o","year":"2007","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1212\/WNL.51.3.708","article-title":"Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy","volume":"51","author":"Plant\u00e9-Bordeneuve","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.006_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/BF02190707","article-title":"Transthyretin Leu 68 in a form of cardiac amyloidosis","volume":"86","author":"Almeida","year":"1991","journal-title":"Basic Res Cardiol"},{"issue":"9","key":"10.1016\/j.hfc.2021.07.006_bib29","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(92)90672-X","article-title":"A\u00a0Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretinmethionine111 variant in serum from patients and carriers","volume":"93","author":"Ranl\u00f8v","year":"1992","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","article-title":"Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: A clinical, genetic, and epidemiological study","volume":"59","author":"Reilly","year":"1995","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"21","key":"10.1016\/j.hfc.2021.07.006_bib32","first-page":"1707","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"40","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.hfc.2021.07.006_bib33","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.hfc.2021.07.006_bib34","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the amyloidosis research consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"issue":"24","key":"10.1016\/j.hfc.2021.07.006_bib35","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib36","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib39","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.hfc.2021.07.006_bib40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Hear Fail"},{"issue":"17","key":"10.1016\/j.hfc.2021.07.006_bib41","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacc.2019.04.054","article-title":"Association of carpal tunnel syndrome with amyloidosis, heart failure, and adverse cardiovascular outcomes","volume":"74","author":"Fosb\u00f8l","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2021.07.006_bib43","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","article-title":"High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly","volume":"42","author":"Sekijima","year":"2011","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/modpathol.2014.102","article-title":"Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis","volume":"28","author":"Yanagisawa","year":"2015","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: Probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci"},{"issue":"10","key":"10.1016\/j.hfc.2021.07.006_bib46","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.hfc.2021.07.006_bib47","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib48","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.hfc.2021.07.006_bib49","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/13506129.2018.1493989","article-title":"Right ventricular involvement in transthyretin amyloidosis","volume":"25","author":"Arvidsson","year":"2018","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcmg.2015.04.012","article-title":"Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis","volume":"9","author":"Longhi","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"47","key":"10.1016\/j.hfc.2021.07.006_bib52","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","article-title":"Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?","volume":"37","author":"Galat","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib53","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.006_bib54","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am J Cardiol"},{"issue":"18","key":"10.1016\/j.hfc.2021.07.006_bib55","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"issue":"6\u20137","key":"10.1016\/j.hfc.2021.07.006_bib56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejheart.2007.01.012","article-title":"Non-invasive predictors of survival in cardiac amyloidosis","volume":"9","author":"Kristen","year":"2007","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"10.1016\/j.hfc.2021.07.006_bib57","doi-asserted-by":"crossref","first-page":"e012097","DOI":"10.1161\/JAHA.119.012097","article-title":"Noninvasive mapping of the electrophysiological substrate in cardiac amyloidosis and its relationship to structural abnormalities","volume":"8","author":"Orini","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.hfc.2021.07.006_bib58","doi-asserted-by":"crossref","unstructured":"Valentini F, Anselmi F, Metra M, et\u00a0al. Diagnostic and prognostic value of low QRS voltages in cardiomyopathies: old but gold. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa027.","DOI":"10.1093\/eurjpc\/zwaa027"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9149(82)90270-3","article-title":"Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation","volume":"49","author":"Carroll","year":"1982","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib60","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"issue":"21","key":"10.1016\/j.hfc.2021.07.006_bib61","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.006_bib63","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Hear Fail"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.006_bib64","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2009.05.040","article-title":"Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring","volume":"104","author":"Goldsmith","year":"2009","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.hfc.2021.07.006_bib65","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1460-9592.2001.01228.x","article-title":"Holter monitoring in AL amyloidosis: prognostic implications","volume":"24","author":"Palladini","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib66","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Hear Rhythm"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/anec.12032","article-title":"Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis","volume":"18","author":"Boldrini","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib68","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Hear Rhythm"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib69","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0735-1097(97)00267-2","article-title":"Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement","volume":"30","author":"Reisinger","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.hfc.2021.07.006_bib70","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib71","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","article-title":"Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis","volume":"9","author":"Ternacle","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0735-1097(90)90183-P","article-title":"Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis","volume":"15","author":"Klein","year":"1990","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.006_bib73","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0735-1097(89)90254-4","article-title":"Doppler characterization of left ventricular diastolic function in cardiac amyloidosis","volume":"13","author":"Klein","year":"1989","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10741-014-9466-3","article-title":"Echocardiography in cardiac amyloidosis","volume":"20","author":"Falk","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"18","key":"10.1016\/j.hfc.2021.07.006_bib75","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.006_bib76","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.006_bib77","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.amjcard.2015.07.008","article-title":"Usefulness of combining electrocardiographic and echocardiographic findings and brain natriuretic peptide in early detection of cardiac amyloidosis in subjects with transthyretin gene mutation","volume":"116","author":"Di Bella","year":"2015","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib78","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1253\/circj.CJ-14-1425","article-title":"Echocardiographic assessment of the cardiac amyloidoses","volume":"79","author":"Koyama","year":"2015","journal-title":"Circ J"},{"issue":"19","key":"10.1016\/j.hfc.2021.07.006_bib79","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1161\/01.CIR.0000068313.67758.4F","article-title":"Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue doppler echocardiography in patients with AL (primary) cardiac amyloidosis","volume":"107","author":"Koyama","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib80","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"10.1016\/j.hfc.2021.07.006_bib81","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","article-title":"Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis. noninvasive imaging compared to endomyocardial biopsy","volume":"51","author":"Vogelsberg","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib82","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib83","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib84","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib85","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis","volume":"3","author":"Syed","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib86","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-014-9470-7","article-title":"Cardiovascular magnetic resonance for amyloidosis","volume":"20","author":"Fontana","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib87","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/mrm.10051","article-title":"Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement","volume":"47","author":"Kellman","year":"2002","journal-title":"Magn Reson Med"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.006_bib88","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib89","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.006_bib90","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2\u2014evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J\u00a0Nucl Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib91","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/13506129.2013.825240","article-title":"Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis","volume":"20","author":"Damy","year":"2013","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.hfc.2021.07.006_bib92","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2459\/JCM.0000000000000349","article-title":"Different NT-proBNP circulating levels for different types of cardiac amyloidosis","volume":"17","author":"Perfetto","year":"2016","journal-title":"J\u00a0Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib93","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","article-title":"Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model","volume":"2","author":"Arvanitis","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"4 PART 1","key":"10.1016\/j.hfc.2021.07.006_bib94","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0002-8703(82)90331-3","article-title":"Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis","volume":"103","author":"Wizenberg","year":"1982","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.006_bib95","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0002-9149(83)80140-4","article-title":"Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis","volume":"51","author":"Falk","year":"1983","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.006_bib96","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib97","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00259-010-1642-7","article-title":"Usefulness and limitations of 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy","volume":"38","author":"Rapezzi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"10.1016\/j.hfc.2021.07.006_bib98","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jacc.2007.12.038","article-title":"Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis","volume":"51","author":"Rapezzi","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib99","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/13506129.2013.871250","article-title":"Bone scintigraphy with 99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis","volume":"21","author":"Glaudemans","year":"2014","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.006_bib101","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1373\/clinchem.2004.046870","article-title":"Diagnostic performance of quantitative \u03ba and \u03bb free light chain assays in clinical practice","volume":"51","author":"Katzmann","year":"2005","journal-title":"Clin Chem"},{"issue":"9727","key":"10.1016\/j.hfc.2021.07.006_bib102","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.hfc.2021.07.006_bib103","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First european consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"24","key":"10.1016\/j.hfc.2021.07.006_bib104","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.hfc.2021.07.006_bib105","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2006.01.042","article-title":"Transthyretin V122I in African Americans with congestive heart failure","volume":"47","author":"Buxbaum","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations\u2217","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"issue":"27","key":"10.1016\/j.hfc.2021.07.006_bib107","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.hfc.2021.07.006_bib108","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"45","key":"10.1016\/j.hfc.2021.07.006_bib109","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"issue":"6 I","key":"10.1016\/j.hfc.2021.07.006_bib110","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.006_bib111","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1586\/14779072.2015.1053872","article-title":"Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists","volume":"13","author":"Vaduganathan","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib112","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncology"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.006_bib113","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/hrt.74.5.541","article-title":"Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: Evidence for atrial electromechanical dissociation","volume":"74","author":"Dubrey","year":"1995","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.006_bib114","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.hfc.2021.07.006_bib115","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hfc.2021.07.006_bib116","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","author":"Hindricks","year":"2020","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.hfc.2021.07.006_bib117","first-page":"1070","article-title":"2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association","volume":"15","author":"Members","year":"2013","journal-title":"EP Eur"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.006_bib118","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","article-title":"Prophylactic pacemaker implantation in familial amyloid polyneuropathy","volume":"9","author":"Algalarrondo","year":"2012","journal-title":"Hear Rhythm"},{"issue":"11","key":"10.1016\/j.hfc.2021.07.006_bib119","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"36","key":"10.1016\/j.hfc.2021.07.006_bib120","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.hfc.2021.07.006_bib121","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.006_bib122","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11748-012-0164-6","article-title":"An unexpected mortality following cardiac surgery: a post-mortem diagnosis of cardiac amyloidosis","volume":"61","author":"Fitzmaurice","year":"2013","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"10.1016\/j.hfc.2021.07.006_bib123","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijcard.2016.04.030","article-title":"Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings","volume":"214","author":"Sperry","year":"2016","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.006_bib124","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.109.849281","article-title":"Cause of complete atrioventricular block after percutaneous aortic valve implantation: Insights from a necropsy study","volume":"120","author":"Moreno","year":"2009","journal-title":"Circulation"},{"issue":"5539","key":"10.1016\/j.hfc.2021.07.006_bib125","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","author":"Hammarstr\u00f6m","year":"2001","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib126","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.hfc.2021.07.006_bib127","article-title":"Pharmacokinetics of patisiran, the first approved rna interference therapy in patients with hereditary transthyretin-mediated amyloidosis","author":"Zhang","year":"2019","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib128","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an rna interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO study","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib131","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.006_bib132","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Casta\u00f1o","year":"2012","journal-title":"Congest Hear Fail"},{"issue":"sup1","key":"10.1016\/j.hfc.2021.07.006_bib133","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13506129.2019.1593133","article-title":"The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition","volume":"26","author":"Wixner","year":"2019","journal-title":"Amyloid"},{"issue":"9","key":"10.1016\/j.hfc.2021.07.006_bib134","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J\u00a0Card Fail"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.006_bib135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13506129.2018.1519507","article-title":"Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center\u2019s experience","volume":"25","author":"Ikram","year":"2018","journal-title":"Amyloid"},{"issue":"8853","key":"10.1016\/j.hfc.2021.07.006_bib136","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","article-title":"Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis","volume":"341","author":"Holmgren","year":"1993","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.hfc.2021.07.006_bib137","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.006_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J\u00a0Hear Lung Transpl"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib139","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","article-title":"Progression of transthyretin amyloid neuropathy after liver transplantation","volume":"75","author":"Liepnieks","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.hfc.2021.07.006_bib140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/13506129.2011.615872","article-title":"Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients","volume":"18","author":"Okamoto","year":"2011","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib141","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00007890-199807270-00016","article-title":"Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis","volume":"66","author":"Stangou","year":"1998","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.006_bib142","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejcts.2007.10.025","article-title":"Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis","volume":"33","author":"Sack","year":"2008","journal-title":"Eur J Cardio-thoracic Surg"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:43:35Z","timestamp":1761554615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713621000751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":142,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1551713621000751"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2021.07.006","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2021.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}